CPC
LGND icon

Cookson Peirce & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Cookson Peirce & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Buy
11,822
+1,232
+12% +$290K 0.12% 89
2026
Q1 		$2.11M Buy
10,590
+443
+4% +$87.6K 0.09% 102
2025
Q4 		$1.92M Buy
10,147
+384
+4% +$73.8K 0.08% 113
2025
Q3 		$1.73M Buy
9,763
+181
+2% +$26.9K 0.07% 116
2025
Q2 		$1.09M Buy
9,582
+667
+7% +$71.3K 0.05% 150
2025
Q1 		$937K Buy
8,915
+1,265
+17% +$143K 0.05% 140
2024
Q4 		$820K Buy
7,650
+2,755
+56% +$311K 0.04% 150
2024
Q3 		$490K Buy
4,895
+1,554
+47% +$156K 0.02% 186
2024
Q2 		$282K Buy
+3,341
New +$266K 0.01% 209
2016
Q3 		– Sell
-103,474
Closed -$7.7M – 150
2016
Q2 		$7.7M Sell
103,474
-11,221
-10% -$833K 1.14% 32
2016
Q1 		$7.66M Sell
114,695
-513
-0.4% -$31.2K 1.21% 31
2015
Q4 		$7.79M Buy
115,208
+257
+0.2% +$15.9K 1.17% 32
2015
Q3 		$6.14M Buy
+114,951
New +$6.97M 1.02% 36

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cookson Peirce & Co's LGND Position: Q2 2026 in Review

Cookson Peirce & Co increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q2 2026, buying an estimated $290K and bringing the position to 11,822 shares worth $3.74M. The position accounts for 0.12% of the portfolio, ranked #89.

Cookson Peirce & Co first reported a position in LGND in Q3 2015 and has held it in 13 quarters since. The position peaked at $7.79M in Q4 2015. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Cookson Peirce & Co held 11,822 shares of Ligand Pharmaceuticals worth $3.74M as of Q2 2026.
  • Cookson Peirce & Co bought 1,232 Ligand Pharmaceuticals shares in Q2 2026, an estimated $290K.
  • Ligand Pharmaceuticals made up 0.12% of Cookson Peirce & Co's portfolio in Q2 2026, its #89 holding.
  • Cookson Peirce & Co first reported a position in Ligand Pharmaceuticals in Q3 2015 and has held it in 13 quarters since.
  • Cookson Peirce & Co's Ligand Pharmaceuticals position peaked at $7.79M in Q4 2015.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cookson Peirce & Co's 13F filing for Q2 2026, filed 23 Jul 2026.